Retrospective study for investigation of proteinuria generation and anti-proteinuria effect of RAS inhibitor in non-small cell lung cancer patients who received bevacizumab chemotherapy(NJLCG1303)

Retrospective study for investigation of proteinuria generation and anti-proteinuria effect of RAS inhibitor in non-small cell lung cancer patients who received bevacizumab chemotherapy(NJLCG1303) - NJLCG1303

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012403

Enrollment

200

Registered

2013-12-01

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-small cell lung cancer patients who received bevacizumab chemotherapy

Exclusion criteria

Exclusion criteria: Patients with diabetes during treatment

Design outcomes

Primary

Measure	Time frame
Proteinuria(1+ or severer dipstick and/or 0.15g/gCr or severer UPCR)	—

Countries

Japan

Contacts

Public ContactSato Junya

Iwate Medical University Department of Pharmacy

junya02377@nifty.com019-651-5111

Outcome results